These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22246902)

  • 1. Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer--novel predictor of biochemical recurrence after radical surgery.
    Mitsui Y; Shiina H; Hiraki M; Arichi N; Hiraoka T; Sumura M; Honda S; Yasumoto H; Igawa M
    Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):487-96. PubMed ID: 22246902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer.
    Enokida H; Shiina H; Igawa M; Ogishima T; Kawakami T; Bassett WW; Anast JW; Li LC; Urakami S; Terashima M; Verma M; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
    Cancer Res; 2004 Sep; 64(17):5956-62. PubMed ID: 15342374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.
    Ogishima T; Shiina H; Breault JE; Tabatabai L; Bassett WW; Enokida H; Li LC; Kawakami T; Urakami S; Ribeiro-Filho LA; Terashima M; Fujime M; Igawa M; Dahiya R
    Clin Cancer Res; 2005 Feb; 11(3):1028-36. PubMed ID: 15709168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypermethylation of the GABRE~miR-452~miR-224 promoter in prostate cancer predicts biochemical recurrence after radical prostatectomy.
    Kristensen H; Haldrup C; Strand S; Mundbjerg K; Mortensen MM; Thorsen K; Ostenfeld MS; Wild PJ; Arsov C; Goering W; Visakorpi T; Egevad L; Lindberg J; Grönberg H; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Clin Cancer Res; 2014 Apr; 20(8):2169-81. PubMed ID: 24737792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylation of Integrin α4 and E-Cadherin Genes in Human Prostate Cancer.
    Mostafavi-Pour Z; Kianpour S; Dehghani M; Mokarram P; Torabinejad S; Monabati A
    Pathol Oncol Res; 2015 Sep; 21(4):921-7. PubMed ID: 25743258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
    Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
    Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia.
    Paradowska A; Fenic I; Konrad L; Sturm K; Wagenlehner F; Weidner W; Steger K
    Int J Oncol; 2009 Jul; 35(1):87-96. PubMed ID: 19513555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
    Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
    Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer.
    Zhao H; Shiina H; Greene KL; Li LC; Tanaka Y; Kishi H; Igawa M; Kane CJ; Carroll P; Dahiya R
    Cancer; 2005 Jul; 104(1):44-52. PubMed ID: 15895377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of high mobility group box 1 with poor prognosis in patients after radical prostatectomy.
    Li T; Gui Y; Yuan T; Liao G; Bian C; Jiang Q; Huang S; Liu B; Wu D
    BJU Int; 2012 Dec; 110(11 Pt C):E1125-30. PubMed ID: 22672360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter CpG-Site Methylation of the KAI1 Metastasis Suppressor Gene Contributes to Its Epigenetic Repression in Prostate Cancer.
    Lee J; Lee MS; Jeoung DI; Kim YM; Lee H
    Prostate; 2017 Mar; 77(4):350-360. PubMed ID: 27813113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of PITX2 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis.
    Vinarskaja A; Schulz WA; Ingenwerth M; Hader C; Arsov C
    Urol Oncol; 2013 Jul; 31(5):622-7. PubMed ID: 21803613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
    Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
    Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
    Pulukuri SM; Rao JS
    Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CpG hypermethylation of the promoter region inactivates the estrogen receptor-beta gene in patients with prostate carcinoma.
    Nojima D; Li LC; Dharia A; Perinchery G; Ribeiro-Filho L; Yen TS; Dahiya R
    Cancer; 2001 Oct; 92(8):2076-83. PubMed ID: 11596023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer.
    Mitsui Y; Chang I; Kato T; Hashimoto Y; Yamamura S; Fukuhara S; Wong DK; Shiina M; Imai-Sumida M; Majid S; Saini S; Shiina H; Nakajima K; Deng G; Dahiya R; Tanaka Y
    Oncotarget; 2016 Aug; 7(31):49107-49121. PubMed ID: 27203547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.